Risankizumab-rzaa (Skyrizi, AbbVie) is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy.
The combination of selinexor and 4-OHT may be able to prevent endocrine resistance in hormone-responsive breast cancer by rewiring gene pathways.
Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis.
Top news of the day from across the health care landscape.
The potential for prescription drugs to cost more than $1 million for a treatment regimen creates a mixed bag of conundrums for the health care system.
Research investigates cytomegalovirus to understand the process of targeting HIV in order to eradicate it from the body.
Top news of the day from across the health care landscape.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.